Phase 2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide Administered With a Pembrolizumab in Patients With Persistent or Recurrent/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Trial Profile

Phase 2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide Administered With a Pembrolizumab in Patients With Persistent or Recurrent/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Dec 2017

At a glance

  • Drugs EMD 640744 (Primary) ; Cyclophosphamide; Pembrolizumab
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms SPiReL
  • Most Recent Events

    • 24 Nov 2017 Last checked against ClinicalTrials.gov record.
    • 08 Nov 2017 According to an Immunovaccine media release, Health Canada has granted Sunnybrook Research Institute regulatory clearance to begin this trial.
    • 31 Aug 2017 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top